ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "proteomics"

  • Abstract Number: 0888 • ACR Convergence 2024

    Genetically Determined Peptidylglycine Alpha-amidating Monooxygenase (PAM) Mediated Amidation Regulates Tissue Damage by Rheumatoid Arthritis Synovial Fibroblasts

    Kevin Sheridan1, Emma Doris1, Maria Pimenta1, Jemma Falkov1, Matthew Fisher2, Munitta Muthana2, Denis Shields1, Richard Mains3, Betty Eipper3, Christopher Buckley4 and Anthony Wilson5, 1University College Dublin, Dublin, Ireland, 2University of Sheffield, Sheffield, United Kingdom, 3University of Connecticut, Connecticut, 4University of Oxford, Oxford, United Kingdom, 5UCD, Dublin, Dublin, Ireland

    Background/Purpose: The SNP rs26232 is associated with both risk and severity of rheumatoid arthritis (RA), with the C allele associated with the susceptibility to RA,…
  • Abstract Number: 1813 • ACR Convergence 2024

    Elucidating the Molecular Correlates of Treatment Response in Lupus Nephritis via Imaging Mass Cytometry Proteomics and Machine Learning

    Frank Sen Hee Tay1, Anto Sam Crosslee Louis Sam Titus2, Vinaika Maruvada2, Sandy Lim1, Jiacai Cho1, Thomas Thamboo1 and Chandra Mohan3, 1National University Hospital, Singapore, Singapore, 2University of Houston, Houston, 3University of Houston, Houston, TX

    Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE).  Despite the advances in the management…
  • Abstract Number: 0895 • ACR Convergence 2024

    Procoagulant Extracellular Vesicles in Patients with Livedo Reticularis

    Avital Baniel1, Cristina Ricco2, Rohan Dhiman3, Ahmed Eldaboush4, Caroline Stone4, Daniella Faden4, Luca Musante4, MIng-lin Liu4 and Victoria Werth5, 1Perelman School of Medicine, UPENN, Philadelphia, PA, 2university of pennsylvania, Philadelphia, 3University of Pennsylvania, Newport Coast, CA, 4University of pennsylvania, Philadelphia, PA, 5University of Pennsylvania, Wynnewood, PA

    Background/Purpose: Procoagulant activity is an important property of EVs. Connective tissue disease (CTD) patients with livedo reticularis (LR) are known for their procoagulant conditions. The…
  • Abstract Number: 1825 • ACR Convergence 2024

    Proteomic and Transcriptomic Analysis Reveal Elevated Senescent Signature in Systemic Sclerosis Fibrosis

    Poulami Dey, Hiroshi Kato, Suiyuan Huang, Johann Gudjonsson, Dinesh Khanna, John Varga and Eliza Pei-Suen Tsou, University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic sclerosis (SSc) is marked by persistent fibrosis affecting both the skin and internal organs. Some regard SSc as a manifestation of expedited aging,…
  • Abstract Number: 0899 • ACR Convergence 2024

    Proteomic Insights into JAK Inhibitor Therapeutic Response in Rheumatoid Arthritis

    Ting-Shuan Wu1 and Yi-Ming Chen2, 1Chung Shan Medical University, Taichung, Taiwan (Republic of China), 2Taichung Veterans General Hospital, Taiwan, Taichung, Taiwan (Republic of China)

    Background/Purpose: Rheumatoid arthritis (RA) is a common and complex inflammatory polyarthritis. Janus kinase inhibitors (JAKi) have shown superior efficacy compared to traditional treatments, but predictors…
  • Abstract Number: 2081 • ACR Convergence 2024

    Proteomic Profiling of Urine Reveals Biomarker Candidates for Idiopathic Inflammatory Myopathies

    Xueting Yuan1, Zhengguang Guo2, Jia Shi1, Shuang Zhou3, Chanyuan Wu4, Jiuliang Zhao3, Dong Xu5, Mengtao Li6, Wei Sun2, qian wang6 and Xiaofeng Zeng7, 1Peking Union Medical College, Beijing, China, 2Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China, 3Peking union medical college hospital, Beijing, China, 4Peking Union Medical College Hospital, Chinese Academy of Medical Sciences& Peking Union Medical College, Beijing, China, 5Peking Union Medical College Hospital, Dong Cheng District, Beijing, China, 6Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, 7Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare heterogeneous group of autoimmune diseases characterized by immune-mediated muscle injury. We aimed to examine urine proteomic signatures…
  • Abstract Number: 0044 • ACR Convergence 2024

    Synovial Phosphoproteomic Profiling in Early and Advanced Rheumatoid Arthritis (R4RA Trial) Identifies Specific Signaling Pathways Linked to Distinct Pathotypes

    Cankut Cubuk1, Rachel Lau1, Vinothini Rajeeve2, Pedro Cutillas2, Rebecca Hands1, Liliane Fossati-Jimack1, Anna Surace1, Alessandra Nerviani1, Felice Rivellese1, Myles Lewis3 and Costantino Pitzalis4, and the R4RA Collaborative Group, 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust, London, EC1M 6BQ, London, United Kingdom, 2Cell Signalling and Proteomics Group, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, London, United Kingdom, 3Queen Mary University of London, London, United Kingdom, 4QMUL, Bromley Kent, United Kingdom

    Background/Purpose: Rheumatoid arthritis (RA) is an incurable autoimmune disease where response to therapy is heterogenous. Clinically indistinguishable RA patients can be classified histo-pathologically into three…
  • Abstract Number: 0906 • ACR Convergence 2024

    Proteomic Signatures of Difficult-to-Treat Rheumatoid Arthritis: Identifying Predictive Biomarkers

    Klára Mocová1, Jiri Baloun1, Aneta Prokopcová2, Kristýna Brábníková Marešová1, Herman Mann3, Jiří Vencovský2, Karel Pavelka4 and Ladislav Šenolt2, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 3Revmatologický ústav, Praha, Czech Republic, 4Institute of Rheumatology and Charles University, Praha, Czech Republic

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction and extra-articular manifestations. Despite the advancements in the…
  • Abstract Number: 2229 • ACR Convergence 2024

    Aptamer Based Proteomic Profiling Demonstrates Significant Differences in Methotrexate Responders versus Non-responders in Newly Diagnosed Rheumatoid Arthritis and Adds Potential Value to Clinical Examination

    Kaien Gu1, Leanne Lac1, Nathalie Carrier2, Liam O'Neil1, Gilles Boire3, Pingzhou Hu4 and Carol Hitchon1, 1University of Manitoba, Winnipeg, MB, Canada, 2Universite de Sherbrooke, Sherbrooke, QC, Canada, 3Retired, Sherbrooke, QC, Canada, 4Western University, London, ON, Canada

    Background/Purpose: Despite methotrexate (MTX) being the cornerstone of rheumatoid arthritis (RA) therapy, uncertainty exists around who will respond to MTX. We aimed to determine the…
  • Abstract Number: 0045 • ACR Convergence 2024

    Proteomic Analysis of the Rheumatoid Arthritis Citrullinome Reveals an Enrichment of Citrullinated Complement Proteins

    Khushali Trivedi1, Clarissa Klenke2, Jun Kim1, Jeba Atkia Maisha2, Alina Sememenko1, XIAOBO MENG2, Mario Navarrete1, Hani El-Gabalawy2 and Liam O'Neil2, 1University of Manitoba, Winnipeg, Canada, 2University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Citrullination is a key physiological process that drives autoantibody formation in Rheumatoid Arthritis (RA). This irreversible post-translational modification of the amino acid arginine is…
  • Abstract Number: 0909 • ACR Convergence 2024

    Identifying Predictive Serum Soluble Mediators Signatures Specific to ANA+ at Risk of SLE Individuals with Next Generation Proteomics

    Aleksandra Bylinska1, Miles Smith1, Rufei Lu1, Benjamin Jones2, Carla Guthridge1, Matthew Caleb Marlin1, Christian Wright3, Susan Macwana3, Wade DeJager3, Marci Beel3, Christopher Lessard1, Cristina Arriens1, Joan Merrill4, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma State University, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, 4Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

    Background/Purpose: Multiple factors can predispose individuals to development of SLE, including the presence of African American ancestry, lupus-associated autoantibodies (ANAs), or some clinical manifestations of…
  • Abstract Number: 2245 • ACR Convergence 2024

    Clinical Efficacy and Molecular Cardiovascular Changes of Baricitinib in Biologic-naïve Patients with Rheumatoid Arthritis. Direct Comparative Analysis with TNF Inhibitors and Conventional DMARDs

    Chary Lopez-Pedrera1, Laura Muñoz-Barrera2, Rafaela Ortega-Castro3, Sagrario Corrales2, Jerusalén Calvo4, Concepción Aranda-Valera5, María Lourdes Ladehesa-Pineda1, Pilar Font2, Ismael Sánchez Pareja2, Elena Moreno-Caño5, María Carmen Ábalos-Aguilera6, Christian Merlo-Ruiz6, Mª Angeles Aguirre-Zamorano7, Tomás Cerdó2, Nuria Barbarroja2, Carlos Perez-Sanchez2 and Alejandro Escudero-Contreras2, 1IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 2IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 3Hospital Reina Sofía, Cordoba, Andalucia, Spain, 4IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 5IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, 6IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Spain, 7IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain

    Background/Purpose: The main objective of this study was to conduct extensive clinical and molecular analyses to accurately characterize the specific effects of Baricitinib (4 mg/day)…
  • Abstract Number: 0113 • ACR Convergence 2024

    Plasma Proteomics Analysis Identifies Thromboinflammatory Signature Associated with Clinical Antiphospholipid Syndrome: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

    Alexander Pine1, Vittorio Pengo2, Savino Sciascia3, Nina Kello4, Rosario Lopez Pedrera5, H Michael Belmont6, David Branch7, Laura Andreoli8, Michelle Petri9, Ricard Cervera10, Jason Knight11, Pierluigi Meroni12, Hannah Cohen13, Rohan Willis14, Maria Laura Bertolaccini15, Alfred Lee16, Doruk Erkan17 and Anish Sharda16, 1Yale School of Medicine/VA Connecticut, West Haven, CT, 2Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, 3University of Turin, Torino, Turin, Italy, 4Northwell Health, Brooklyn, NY, 5IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 6NYU School of Medicine, New York, NY, 7University of Utah and Intermountain Healthcare, Salt Lake City, UT, 8University of Brescia, Brescia, Italy, 9Johns Hopkins University School of Medicine, Timonium, MD, 10Hospital Clinic de Barcelona, Barcelona, Spain, 11University of Michigan, Ann Arbor, MI, 12IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, 13University College London Hospitals NHS Foundation Trust, London, United Kingdom, 14University of Texas Medical Branch, Galveston, TX, 15King's College London, London, United Kingdom, 16Yale School of Medicine, New Haven, CT, 17Hospital for Special Surgery, New York, NY

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thromboembolic and obstetric morbidity arising via a model of immunothrombosis. Patients may present with thrombotic (tAPS),…
  • Abstract Number: 0961 • ACR Convergence 2024

    Multi-omics Study of Systemic Sclerosis Immunoglobulins G Effects on Endothelial Cells: A Distinct Profile in Anti-Topoisomerase I Positive Patients

    Aurélien Chepy1, Solange Vivier2, Abderrahmane Elhannani2, Fabrice Bray3, Clément Chauvet4, Martin Figeac5, Lucile Guilbert4, Eric HACHULLA6, Christian Rolando3, Sylvain Dubucquoi4, David Launay4 and Vincent sobanski4, 1Univ. Lille, Inserm, CHU Lille, U1286—INFINITE—Institute for Translational Research in Inflammation, Lille, France., Lille, Nord-Pas-de-Calais, France, 2Univ. Lille, Inserm, CHU Lille, U1286—INFINITE—Institute for Translational Research in Inflammation, Lille, France., Lille, France, 3Univ. Lille, CNRS, USR 3290 - MSAP - Miniaturisation pour la Synthèse l’Analyse et la Protéomique, F-59000 Lille, France, Lille, France, 4Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France., Lille, France, 5Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000 Lille, France, Lille, France, 6CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., LILLE, France

    Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous connective tissue disease characterized by autoimmunity, fibrosis and vasculopathy. Antinuclear antibodies (ANA) are strong diagnostic and prognosis biomarkers…
  • Abstract Number: 2263 • ACR Convergence 2024

    The Potential Use of Circulating Extracellular Vesicles for Improved Diagnosis and Therapy in Rheumatic Inflammatory/autoimmune Diseases: Proof of Concept Studies

    Gilad Halpert1, Ori Moskovitch2, Linoy Israel2, Eri Govrin2, Boris Gilburd2, Ori Segal2, Adi Anaki3, Tal Caller2, Daniel Yechiali2, Shlomo Segev2, Omer Gendelman4, Abdulla Watad5, Ruty Mehrian-Shai2, Rachella Popovtzer3 and Howard Amital6, 1CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, 2Sheba Medical Center, Ramat-Gan, Israel, 3Bar Ilan University, Ramat-Gan, Israel, 4Sheba Medical Center, Ramat Gan, Israel, 5Tel Hashomer Medical Center, Ramat Gan, Israel, 6Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel

    Background/Purpose: Many patients with rheumatic conditions do not completely respond or are refractory to biological therapy. Therefore, there are unmet medical needs in the treatment…
  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology